Lupin unveils generic equivalent of Hectorol Injection

Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials, is the therapeutic generic equivalent of Sanofi Genzyme’s Hectorol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials, Lupin said.

Mumbai: Pharma major Lupin Limited (Lupin) recently announced the launch of Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

It is indicated for the treatment of secondary hyperparathyroidism in adult patients with CKD on dialysis.

Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials, is the therapeutic generic equivalent of Sanofi Genzyme’s Hectorol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials, Lupin said.

Read Also: Lupin partner Concord gets USFDA nod for generic version of Myfortic tablets

Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials, (RLD: Hectorol) had annual sales of approximately USD 132 million in the U.S. (IQVIA MAT October 2019).

Based in Mumbai Lupin Ltd's key focus areas include pediatrics, cardiovascular, anti-infectives, diabetology, asthma, and anti-tuberculosis.

Read Also: NPPA show-cause notices to Sun Pharma, Glenmark, Abbott, Lupin for self-exemption from price cap for anti-diabetic drugs